𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mitomycin-C, VP16-213 combination as third line chemotherapy in advanced breast cancer

✍ Scribed by G. Perez Manga; P. L. Madrigal Alonso; H. Alburquerque Carbuccia

Publisher
Springer
Year
1982
Tongue
English
Weight
199 KB
Volume
7
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Cisplatin plus VP-16 combination chemoth
Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer
✍ Dr. Fikri IΓ§li; Nazan GΓΌunel; Dilek DinΓ§lol; Handan KaraoΗ§uz; Ahmet Demirkazik πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 224 KB

Twenty-nine patients with advanced refractory breast cancer were treated with cisplatin 20 mg/m2/d and VP-16 100 mg/d for 5 days every 3 4 weeks. Ten patients received mitomycin C 10 mg/m2 every 6 weeks additionally. Partial response was obtained in 10 of 26 evaluable patients (38%). The response ra

First-line combination chemotherapy with
First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer
✍ P. Periti; G. Robustelli Delia Cuna; F. Pannuti; T. Mazzei; P. Preti; A. Martoni πŸ“‚ Article πŸ“… 1985 πŸ› Springer US 🌐 English βš– 312 KB

In this study, 30 evaluable patients with advanced carcinoma of the breast were treated with cyclophosphamide 600 mg/m2 i.v. followed one day later with mitoxantrone (Novantrone; dihydroxyanthracenedione) 16 mg/m2 i.v. Drug treatment was repeated every 3-4 weeks, for a maximum of 12 cycles. The over